Earnings summaries and quarterly performance for Maze Therapeutics.
Research analysts covering Maze Therapeutics.
Recent press releases and 8-K filings for MAZE.
Maze Therapeutics Provides Clinical Program Updates
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics expects to release MZE829 data for APOL1-mediated kidney disease (AMKD) later this quarter (Q1 2026), with a target of at least a 30% reduction in UACR for clinical proof of concept.
- The company plans to initiate two Phase 2 studies for MZE782 later this year (2026): one for Phenylketonuria (PKU) in Q2 2026 and another for Chronic Kidney Disease (CKD) in H2 2026.
- MZE829 aims to be the first to show clinical proof of concept in the broad AMKD patient population, with a mechanism that both blocks and disrupts the assembly of the APOL1 pore, distinguishing it from competitors.
- For MZE782, Maze believes it has best-in-class properties for PKU, demonstrating over 40-fold increase in urinary Phe biomarker compared to a competitor's 10-fold increase, aiming to achieve plasma Phe levels below 360 micromolars.
Feb 11, 2026, 8:00 PM
Maze Therapeutics Details Clinical Development for Kidney and Metabolic Diseases
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics anticipates releasing MZE829 clinical data for APOL1-mediated kidney disease (AMKD) in Q1 2026, targeting at least a 30% reduction in UACR from approximately 20 patients.
- The company plans to initiate two Phase 2 studies for MZE782 in 2026: one for PKU in Q2 2026 and another for Chronic Kidney Disease (CKD) in the second half of 2026.
- MZE829's mechanism of action is designed to both block the pore and disrupt its assembly in kidney cells, differentiating it from other therapies.
- For PKU, MZE782 demonstrated best-in-class properties in preclinical data, showing a 40-fold increase in urinary Phe biomarker compared to a competitor's 10-fold, with the goal of reducing plasma Phe below 360 micromolars.
Feb 11, 2026, 8:00 PM
Maze Therapeutics Provides Updates on MZE829 and MZE782 Clinical Programs
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics anticipates releasing data for its MZE829 program in APOL1-mediated kidney disease (AMKD) later this quarter (Q1 2026), targeting at least a 30% reduction in UACR for clinical proof of concept.
- The company plans to initiate two Phase 2 studies for its MZE782 program in 2026: one for PKU (a rare metabolic disease) in Q2 and another for CKD in the second half of the year.
- MZE782 has demonstrated promising preclinical and healthy volunteer data, including over a 40-fold increase in urinary Phe biomarker for PKU and superior proteinuria reduction compared to SGLT2 in preclinical CKD models.
Feb 11, 2026, 8:00 PM
Maze Therapeutics Enters into $200 Million Loan Agreement
MAZE
Debt Issuance
- On February 4, 2026, Maze Therapeutics, Inc. entered into a senior secured term loan facility with Hercules Capital, Inc. for an aggregate principal amount of up to $200.0 million.
- An initial term loan of $40.0 million was funded on the closing date, providing approximately $38.4 million in net proceeds after deducting estimated debt issuance costs and fees.
- The facility has a maturity date of February 1, 2031, and accrues interest at an annual rate determined by the prime rate, with interest rate floors ranging from 7.95% to 9.25% depending on the tranche.
- In connection with this new agreement, the Company's previous Loan and Security Agreement with Banc of California was terminated effective February 2, 2026.
Feb 4, 2026, 9:45 PM
Maze Therapeutics Provides Pipeline Updates and Financial Outlook at J.P. Morgan Healthcare Conference
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics expects to deliver top-line proof-of-concept data for MZE829 for APOL1-mediated kidney disease by the end of Q1 2026.
- The company plans to initiate its Phase 2 study for MZE782 in PKU by mid-2026 and its kidney disease program for MZE782 by the end of 2026.
- Maze Therapeutics has operating capital into 2028, which is sufficient to support all described near-term milestones and catalysts.
- MZE829 targets at least 250,000 individuals in the U.S. with APOL1-mediated kidney disease, with a goal of achieving at least a 30% reduction in UACR.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Outlines Key Catalysts for MZE829 and MZE782 Programs
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics is reiterating guidance to deliver top-line proof-of-concept data for MZE829 in APOL1 kidney disease by the end of Q1 2026, with positive results expected to initiate planning for a Phase IIB/III study.
- The company plans to initiate a Phase II study for MZE782 in PKU by the middle of 2026 and a Phase II study for MZE782 in chronic kidney disease by the end of 2026.
- Maze Therapeutics maintains a strong capital position, with operating capital secured into 2028, funding all described near-term milestones and catalysts.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Provides Pipeline Updates and Financial Outlook
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics reiterated its guidance to deliver top-line proof-of-concept data for MZE829 in APOL1-mediated kidney disease by the end of Q1 2026. Positive results would lead to planning for a Phase 2B3 study.
- The company announced plans to initiate its MZE782 PKU study by mid-2026 and its MZE782 kidney disease program study by the end of 2026.
- Maze Therapeutics reported a strong capital position, with operating capital secured into 2028, funding all near-term milestones and catalysts.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Provides Pipeline Updates and Financial Runway
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics anticipates reporting topline Phase 2 proof-of-concept data for MZE829 in APOL1-mediated Kidney Disease (AMKD) by the end of Q1 2026.
- The company plans to initiate Phase 2 trials for MZE782 in Phenylketonuria (PKU) by mid-2026 and in Chronic Kidney Disease (CKD) in 2H 2026.
- As of September 30, 2025, Maze Therapeutics reported $383.9 million in cash, cash equivalents, and marketable securities, which is expected to provide operating capital into 2028 based on its current business plan.
Jan 12, 2026, 12:00 PM
Maze Therapeutics Reviews 2025 Accomplishments and Prepares for Key Q1 2026 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics achieved significant milestones in 2025, including going public, initiating the MZE829 study for APOL1 kidney disease, releasing additional data for its MZE782 program, and completing a small PIPE financing.
- The company anticipates data from its Horizon study for MZE829 in APOL1 kidney disease by the end of Q1 2026. This data is expected to show a 30% reduction in proteinuria (measured by UACR) in broad APOL1-mediated kidney disease (AMKD) patients, which would be considered clinically significant.
- MZE829 is differentiated from competitors, such as Vertex's inaxaplin, by its dual mechanism of action, which involves both blocking the pore and disrupting its assembly, whereas inaxaplin only blocks the pore.
- Following a successful MZE829 readout, Maze Therapeutics plans to initiate planning for a Phase 2b/3 study. Additionally, the company will begin two Phase 2 studies for its MZE782 program in 2026, building on positive data released in September.
Dec 3, 2025, 3:25 PM
Maze Therapeutics Discusses 2025 Accomplishments and Upcoming MZE829 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics experienced a transformative 2025, marked by going public, initiating its MZE829 study for APOL1 kidney disease, and presenting additional data for MZE782, supported by a PIPE financing.
- The company expects to deliver MZE829 Phase 2 data for APOL1 kidney disease by the end of Q1 2026, with a key target of demonstrating at least a 30% reduction in proteinuria (UACR) in broad AMKD patients.
- MZE829 is differentiated by its dual mechanism of blocking the APOL1 pore and disrupting its assembly, which is believed to offer greater potency compared to competitors.
- Following a successful MZE829 data readout, Maze plans to initiate planning for a Phase 2b/3 study, and also intends to start two Phase 2 studies for MZE782 in 2026 after positive data in September 2025.
Dec 3, 2025, 3:25 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more